Raloxifene News and Research

RSS
Raloxifene is an oral selective estrogen receptor modulator (SERM) that has oestrogenic actions on bone and anti-oestrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.
First Edition: January 10, 2014

First Edition: January 10, 2014

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Anastrozole drug: An effective new option for breast cancer prevention for postmenopausal women

Genetic variations can identify women who are likely to benefit from breast cancer prevention drug

Genetic variations can identify women who are likely to benefit from breast cancer prevention drug

Gene variants may predict which women are most likely to benefit from breast cancer therapy

Gene variants may predict which women are most likely to benefit from breast cancer therapy

Genetic variations may help predict breast cancer risk in women who receive preventive therapy

Genetic variations may help predict breast cancer risk in women who receive preventive therapy

Findings provide basis for reinvigoration of research efforts in breast cancer prevention

Findings provide basis for reinvigoration of research efforts in breast cancer prevention

Web-based decision guide reduces uncertainty about breast cancer prevention options

Web-based decision guide reduces uncertainty about breast cancer prevention options

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

Current Medical Research & Opinion publishes new data on EVISTA for postmenopausal osteoporosis

Exemestane reduces risk of breast cancer in high-risk, postmenopausal women

Exemestane reduces risk of breast cancer in high-risk, postmenopausal women

Drugs for prevention of breast cancer

Drugs for prevention of breast cancer

Drugs can prevent risk of breast cancer in women, experts say

Drugs can prevent risk of breast cancer in women, experts say

USPSTF recommends women of ages 65 and above to routinely screen for osteoporosis

USPSTF recommends women of ages 65 and above to routinely screen for osteoporosis

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Estrogen receptor beta inactivates critical genes, arrests cancer cell growth

Women and cancer today

Women and cancer today

Medtronic's Xpander II receives FDA clearance for vertebral compression fractures

Medtronic's Xpander II receives FDA clearance for vertebral compression fractures

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

14 global studies on osteoporosis medications FORTEO and EVISTA to be presented at ASBMR 2010

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Ligand launches Viviant in Japan and Spain for postmenopausal osteoporosis

Raloxifene drug may be useful in treating kidney disease in women: Study

Raloxifene drug may be useful in treating kidney disease in women: Study

Medtronic launches new KYPHON Express Curette for scraping or scoring bone in the spine

Medtronic launches new KYPHON Express Curette for scraping or scoring bone in the spine

Fred Hutchinson Center offers research-based tip sheets on breast cancer

Fred Hutchinson Center offers research-based tip sheets on breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.